Q2 2024 Earnings Summary
- Significant Growth Potential in Patient Affordability Business: The company has a strong pipeline with the majority of opportunities coming from new clients, indicating substantial potential for revenue growth. Matthew Turner, an executive, stated that "the lion's share of that pipeline is going to be new clients".
- Large Total Addressable Market (TAM): The patient affordability business has an estimated TAM of over $500 million, suggesting significant room for expansion. Matthew Turner mentioned, "we believe right now, the TAM is north of $500 million".
- Improving Operating Leverage and Profitability: The company is demonstrating operating leverage, with adjusted EBITDA margins improving to 15.6% this quarter from 10.3% last year, indicating scalability and increasing profitability. Jeffery Baker highlighted, "we did 15.6% this quarter, up from 10.3% last year".
- The company's contracts with pharmaceutical clients often include termination clauses that allow clients to exit agreements if they are unhappy with the services provided. This presents a risk of losing key clients and revenue if the company fails to maintain high service levels.
- Expanding the patient affordability business requires significant investment in personnel and technology. As new programs are added, the company must hire additional account managers, claims analysts, and call center staff, which may limit operating leverage and impact margins.
- The patient affordability market is primarily a byproduct of the U.S. healthcare system and does not exist in the same form internationally, limiting the company's growth opportunities to the domestic market.
-
Pipeline Growth
Q: Is the pipeline growth mainly from new clients?
A: The majority of our pipeline is from new clientele, though there's a mix; existing clients are adding programs, but until the end of next year, the lion's share will be new clients, many launching multiple programs at once. -
Operating Leverage
Q: Can SG&A expenses leverage as revenues grow?
A: We're seeing operating leverage, with adjusted EBITDA margin increasing to 15.6% this quarter from 10.3% last year. However, we're investing ahead of growth, reflected in our $30-plus million SG&A guidance for the year, as we hire staff before new programs launch. -
Total Addressable Market
Q: What's the total TAM for this business worldwide?
A: Patient affordability programs like ours are primarily a U.S. phenomenon; globally, they don't exist in the same form. We estimate the U.S. TAM to be north of $500 million, based on industry trends and consultations. -
Contract Structure
Q: Can clients exit contracts if dissatisfied?
A: We have master service agreements typically ranging from two to five years, but clients can leave if unhappy, as some contracts contain opt-outs. We focus on service quality to retain clients, earning their business every day. -
Client Diversification
Q: How many pharma companies are you working with now?
A: We're working with over 40%, including direct relationships and through hubs representing multiple companies, making the exact number complex to state.
Research analysts covering Paysign.